Emerging therapeutic strategies for Fragile X Syndrome: Q&A

Ghassan Alusi; Elizabeth Berry-Kravis; David  Nelson; Lauren L Orefice; Sam A Booker

doi:10.1021/acschemneuro.2c00674

Emerging therapeutic strategies for Fragile X Syndrome: Q&A

Ghassan Alusi, Elizabeth Berry-Kravis, David Nelson, Lauren L Orefice, Sam A Booker^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

Abstract / Description of output

Understanding how best to treat aspects of Fragile X syndrome has the potential to improve the quality of life of affected individuals. Such an effective therapy has, as yet, remained elusive. In this article, we ask those researching or affected by Fragile X syndrome their views on the current state of research and from where they feel the most likely therapy may emerge.

Original language	English
Pages (from-to)	3544-3546
Journal	ACS Chemical Neuroscience
Volume	13
Issue number	24
Early online date	7 Dec 2022
DOIs	https://doi.org/10.1021/acschemneuro.2c00674
Publication status	Published - 21 Dec 2022

Keywords / Materials (for Non-textual outputs)

Fragile X syndrome
arbaclofen
fragile X messenger ribonucleoprotein 1
neurodevelopmental conditions
phosphodiesterase
somatosensation

Access to Document

10.1021/acschemneuro.2c00674

acschemneuro.2c00674Final published version, 647 KBLicence: Creative Commons: Attribution (CC-BY)

Cite this

@article{e2c236d6b5174f1d8ae49773466eb52f,

title = "Emerging therapeutic strategies for Fragile X Syndrome: Q&A",

abstract = "Understanding how best to treat aspects of Fragile X syndrome has the potential to improve the quality of life of affected individuals. Such an effective therapy has, as yet, remained elusive. In this article, we ask those researching or affected by Fragile X syndrome their views on the current state of research and from where they feel the most likely therapy may emerge.",

keywords = "Fragile X syndrome, arbaclofen, fragile X messenger ribonucleoprotein 1, neurodevelopmental conditions, phosphodiesterase, somatosensation",

author = "Ghassan Alusi and Elizabeth Berry-Kravis and David Nelson and Orefice, {Lauren L} and Booker, {Sam A}",

year = "2022",

month = dec,

day = "21",

doi = "10.1021/acschemneuro.2c00674",

language = "English",

volume = "13",

pages = "3544--3546",

journal = "ACS Chemical Neuroscience",

issn = "1948-7193",

publisher = "American Chemical Society",

number = "24",

}

TY - JOUR

T1 - Emerging therapeutic strategies for Fragile X Syndrome

T2 - Q&A

AU - Alusi, Ghassan

AU - Berry-Kravis, Elizabeth

AU - Nelson, David

AU - Orefice, Lauren L

AU - Booker, Sam A

PY - 2022/12/21

Y1 - 2022/12/21

N2 - Understanding how best to treat aspects of Fragile X syndrome has the potential to improve the quality of life of affected individuals. Such an effective therapy has, as yet, remained elusive. In this article, we ask those researching or affected by Fragile X syndrome their views on the current state of research and from where they feel the most likely therapy may emerge.

AB - Understanding how best to treat aspects of Fragile X syndrome has the potential to improve the quality of life of affected individuals. Such an effective therapy has, as yet, remained elusive. In this article, we ask those researching or affected by Fragile X syndrome their views on the current state of research and from where they feel the most likely therapy may emerge.

KW - Fragile X syndrome

KW - arbaclofen

KW - fragile X messenger ribonucleoprotein 1

KW - neurodevelopmental conditions

KW - phosphodiesterase

KW - somatosensation

U2 - 10.1021/acschemneuro.2c00674

DO - 10.1021/acschemneuro.2c00674

M3 - Comment/debate

C2 - 36475635

SN - 1948-7193

VL - 13

SP - 3544

EP - 3546

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

IS - 24

ER -

Emerging therapeutic strategies for Fragile X Syndrome: Q&A

Abstract / Description of output

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Cite this